Drug
Fremanezumab clinical trials
Also written TEV-48125 and Ajovy.
- studies test it
- 29
- open now
- 2
- in phase 3
- 14
- first study started
- 2013
Keep track of what changes. Save the fremanezumab studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Name
Brand
Development codes
Studies by the year they started
27 studies that test it; most in 2017 (8); 2 more planned to start later
| Year | Studies |
|---|---|
| 2013 | 1 |
| 2014 | 2 |
| 2016 | 3 |
| 2017 | 8 |
| 2019 | 2 |
| 2020 | 5 |
| 2021 | 3 |
| 2022 | 2 |
| 2024 | 1 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 2
- Phase 2
- 8
- Phase 3
- 14
- Phase 4
- 6
- No phase
- 1
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 23 · Other 6
Teva Branded Pharmaceutical Products R&D, Inc. (17) · Otsuka Pharmaceutical Co., Ltd. (3) · Brigham and Women's Hospital (1) · Teva Branded Pharmaceutical Products R&D LLC (1) · David True (1) · M.D. Anderson Cancer Center (1) · Insel Gruppe AG, University Hospital Bern (1) · Beth Israel Deaconess Medical Center (1)
Often tested with
Tested in the same studies.
Prednisone (1) · Eptinezumab (1) · Erenumab (1) · Onabotulinum toxin A (1) · Galcanezumab (1)
Studies
Open first, then newest update. How each study uses fremanezumab is read from its arms, and is right about nine times in ten.
Testing it · 29
- Proactively Intervening On Early Cranial Nerve Injury As A Delayed Sequela Of Oropharyngeal Cancer: A Randomized Feasibility Clinical Trial For Pro-Habilitation (proNERVE RCT)Not yet recruitingPhase 1M.D. Anderson Cancer CenterNCT07832266Written as Ajovy
- Calcitonin Gene-related Peptide Antibody in Acute Mountain SicknessNot yet recruitingPhase 4Insel Gruppe AG, University Hospital BernNCT07653516Written as Fremanezumab 225 Mg/1.5 mL Subcutaneous Solution
- Fremanezumab Treatment of Migraine in Women With Menstrual Migraine Ages 18-45CompletedPhase 4Brigham and Women's HospitalNCT06173661Written as Fremanezumab
- A Trial to Test if Fremanezumab is Effective in Preventing Migraine in Children and AdolescentsCompletedPhase 3Teva Branded Pharmaceutical Products R&D LLCNCT04530110Written as Fremanezumab
- A Study to Test if Fremanezumab is Effective in Preventing Episodic Migraine in Patients 6 to 17 Years of AgeCompletedPhase 3Teva Branded Pharmaceutical Products R&D, Inc.NCT04458857Written as Fremanezumab
- Fremanezumab, Migraine and SleepTerminatedPhase 4Beth Israel Deaconess Medical CenterNCT04693533Written as Fremanezumab Prefilled Syringe [Ajovy]
- A Study to Test if Fremanezumab is Effective in Preventing Chronic Migraine in Participants 6 to 17 Years of AgeCompletedPhase 3Teva Branded Pharmaceutical Products R&D, Inc.NCT04464707Written as Fremanezumab
- A Randomized, Double-Blind, Placebo-Controlled Study With an Open-Label Period on Efficacy and Safety of Fremanezumab in Chinese Adults With MigraineCompletedPhase 3Teva Branded Pharmaceutical Products R&D, Inc.NCT05458011Written as Fremanezumab
- Real World Effectiveness of Eptinezumab in Participants With MigraineTerminatedPhase 4H. Lundbeck A/SNCT05284019Written as Fremanezumab
- A Study to Evaluate the Efficacy and Safety of Fremanezumab for Preventive Treatment of Migraine in Patients With Major Depressive DisorderCompletedPhase 4Teva Branded Pharmaceutical Products R&D, Inc.NCT04041284Written as Fremanezumab
- A Study to Test the Effectiveness and Safety of Fremanezumab on Participants With FibromyalgiaTerminatedPhase 2Teva Branded Pharmaceutical Products R&D, Inc.NCT03965091Written as Fremanezumab
- Long-term Safety and Tolerability of Subcutaneous Administration of TEV-48125 for the Preventive Treatment of MigraineCompletedPhase 3Otsuka Pharmaceutical Co., Ltd.NCT03303105Written as TEV-48125
- A Study to Test if Fremanezumab Reduces Headache in Participants With Posttraumatic Headache (PTH)CompletedPhase 2Teva Branded Pharmaceutical Products R&D, Inc.NCT03347188Written as Fremanezumab
- Efficacy of AJOVY (Fremanezumab-vfrm) on Interictal Migraine Related BurdenCompletedPhase 4David TrueNCT04461795Written as Fremanezumab-Vfrm 225 MG/1.5 ML Subcutaneous Solution [AJOVY]
- Safety and Efficacy of Fremanezumab for Migraine in Adult CADASILWithdrawnPhase 2Mayo ClinicNCT04334408Written as Fremanezumab
- A Multicenter Assessment of LBR-101 in High Frequency Episodic MigraineCompletedPhase 2Teva Branded Pharmaceutical Products R&D, Inc.NCT02025556Written as LBR-101 High Dose
- Assessment of LBR-101 In Chronic MigraineCompletedPhase 2Teva Branded Pharmaceutical Products R&D, Inc.NCT02021773Written as LBR-101 High Dose
- Comparing Efficacy and Safety of 2 Dose Regimens of Subcutaneous Administration of TEV-48125 Versus Placebo for the Preventive Treatment of Chronic MigraineCompletedPhase 3Teva Branded Pharmaceutical Products R&D, Inc.NCT02621931Written as Fremanezumab
- An Efficacy and Safety Study of Fremanezumab in Adults With MigraineCompletedPhase 3Teva Branded Pharmaceutical Products R&D, Inc.NCT03308968Written as Fremanezumab
- Efficacy and Safety of Subcutaneous Administration of Fremanezumab (TEV-48125) for the Preventive Treatment of MigraineCompletedPhase 3Teva Branded Pharmaceutical Products R&D, Inc.NCT02638103Written as Fremanezumab
Codes
What other systems call fremanezumab · ClinicalTrials.gg INT000387
- UNII (FDA) PF8K38CG54FREMANEZUMABConfirmed FDA, Wikidata
- RxNorm 2056691Confirmed FDA, Wikidata
- Wikidata Q39048381fremanezumabConfirmed FDA, Wikidata
- NCI Thesaurus C174842FremanezumabOne source FDA
- DrugBank DB14041One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | PF8K38CG54 | FREMANEZUMAB | Confirmed FDA, Wikidata |
| RxNorm | 2056691 | — | Confirmed FDA, Wikidata |
| Wikidata | Q39048381 | fremanezumab | Confirmed FDA, Wikidata |
| NCI Thesaurus | C174842 | Fremanezumab | One source FDA |
| DrugBank | DB14041 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.